Suchergebnisse - "Rizvi, Hira"

PubPharm (6)

1

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

enthalten in: Cell | 2020

von Nabet, B. | Esfahani, M. | Moding, E. | +29

CommentIn: Cell. 2020 Oct 15;183(2):303-304. - PMID 33064985

2

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Osorio, J. | Arbour, K. | Le, D. | +14

3

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Tio, M. | Rai, R. | Ezeoke, O. | +22

4

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Arbour, K. | Mezquita, L. | Long, N. | +16

CommentIn: Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S364-S368. - PMID 32038916

5

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Leonardi, G. | Gainor, J. | Altan, M. | +8

6

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Naidoo, J. | Wang, X. | Woo, K. | +26

CommentIn: J Clin Oncol. 2017 May 10;35(14):1628-1629. - PMID 28165902

1
[1]